| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a6b928fbe43101d5c4203929fcf8d71 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate |
2002-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8b17af5ba92f195a7b26948d23e8721
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7219a86d3389e14282e3000800dfedd4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df18156eced02dd436b33cb89505a2dd |
| publicationDate |
2011-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-570295-A |
| titleOfInvention |
28 day oral contraceptive regime package |
| abstract |
Disclosed is a package comprising: (a) 21 dosage forms comprising estrogen and progestin, wherein: the estrogen in each of the dosage forms is present in a daily amount equivalent to 5 micrograms to 50 micrograms of ethinyl estradiol, and the progestin in each of the dosage forms is present in a daily amount equivalent to 0.05 mg to 1.5 mg of desogestrel; and (b) 7 dosage forms comprising estrogen, wherein the estrogen in each of thedosage forms is present in a daily amount equivalent to 5 micrograms to 50 micrograms ofethinyl estradiol; wherein the dosage forms are in an arrangement in the package in a fixed sequence corresponding to the stages of daily oral administration, the arrangement being such as to dictate sequential and continuous daily administration of each of the 21 dosage forms comprising estrogen and progestin in (a) each day for 21 consecutive days followed consecutively by sequential and continuous daily administration of each of the 7 dosage forms comprising estrogen in (b) each day for 7 consecutive days. Also disclosed is a method for contraception. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8415332-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8450299-B2 |
| priorityDate |
2001-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |